← FDA DRUG APPROVALS

FDA ANDA · ANDA065418

CEFDINIR

Sponsor: ANDA REPOSITORY

APPLICATION
ANDA065418
TYPE
ANDA
ORIGINAL APPROVAL
2007-07-18
LATEST ACTION
2020-08-21
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription

Products

CEFDINIRPrescription
CEFDINIR 300MG · CAPSULE · ORAL

Approval history

2020-08-21Labeling · Supplement 9 · standardAP
2010-05-27Labeling · Supplement 6AP
2009-07-20Labeling · Supplement 4AP
2008-09-18Labeling · Supplement 2AP
2008-02-07Labeling · Supplement 1AP
2007-07-18OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →